SecSonar.com

Nexera Technologies Ltd (NEXR)

Nexera Technologies Ltd at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Nexera Technologies Ltd (NEXR) is a Biotechnology company based in IL with a market capitalization of $1M. Revenue grew 22.9% year-over-year and free cash flow was negative at -$6.4M. This page tracks NEXR's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

IL · 11 employees · IPO Apr 2, 2026

Valuation

Valuation & price

$1.44 · as of May 17, 2026 · -66.3% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

0.09

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$4.27$2.42$0.56Mar 26Apr 26Jul 26Mar 2, 26$3.94Mar 3, 26$3.93Mar 4, 26$4.19Mar 5, 26$4.11Mar 6, 26$4.27Mar 9, 26$4.11Mar 10, 26$4.20Mar 11, 26$4.03Mar 12, 26$3.84Mar 13, 26$3.92Mar 16, 26$4.00Mar 17, 26$4.07Mar 18, 26$4.00Mar 19, 26$3.92Mar 20, 26$3.77Mar 23, 26$3.66Mar 24, 26$3.28Mar 25, 26$2.89Mar 26, 26$2.52Mar 27, 26$2.20Mar 30, 26$3.08Mar 31, 26$2.27Apr 1, 26$1.91Apr 2, 26$1.96Apr 6, 26$1.93Apr 7, 26$1.70Apr 8, 26$1.78Apr 9, 26$1.78Apr 10, 26$1.79Apr 13, 26$1.89Apr 14, 26$1.86Apr 15, 26$1.92Apr 16, 26$2.03Apr 17, 26$2.03Apr 20, 26$2.03Apr 21, 26$2.14Apr 22, 26$2.11Apr 23, 26$2.00Apr 24, 26$1.84Apr 27, 26$2.00Apr 28, 26$2.30Apr 29, 26$2.19Apr 30, 26$2.43May 1, 26$2.22May 4, 26$2.07May 5, 26$2.21May 6, 26$1.84May 7, 26$1.87May 8, 26$1.73May 11, 26$1.66May 12, 26$1.50May 13, 26$1.53May 14, 26$1.40May 15, 26$1.44May 18, 26$1.37May 19, 26$1.34May 20, 26$1.26May 21, 26$1.20May 22, 26$1.21May 26, 26$1.19May 27, 26$1.10May 28, 26$1.16May 29, 26$1.36Jun 1, 26$1.34Jun 2, 26$1.20Jun 3, 26$1.02Jun 4, 26$1.56Jun 5, 26$1.21Jun 8, 26$0.93Jun 9, 26$0.80Jun 10, 26$0.76Jun 11, 26$0.77Jun 12, 26$0.71Jun 15, 26$0.73Jun 16, 26$0.70Jun 17, 26$0.73Jun 18, 26$0.69Jun 22, 26$0.66Jun 23, 26$0.63Jun 24, 26$0.56Jun 25, 26$1.10Jun 26, 26$0.81Jun 29, 26$0.79Jun 30, 26$0.67Jul 1, 26$0.68Jul 2, 26$0.64
$0.5652-week range$4.27
Loading valuation history…

Fundamentals

Key fundamentals

$1M

Market cap

22.9%

Revenue growth (YoY)

3.4%

Gross margin

-$6.4M

Free cash flow (USD)

$3.8M

Net debt

1548.1%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2019 → 2025

FY 2019$670.0KFY 2020$2.3MFY 2021$6.5MFY 2022$5.9MFY 2023$10.0MFY 2024$13.7MFY 2025$16.8M
$670K$16.8M

Free cash flow by year

2019 → 2025

FY 2019$-237.0KFY 2020$125.0KFY 2021$-865.0KFY 2022$-4.9MFY 2023$-4.4MFY 2024$-6.3MFY 2025$-6.4M
-$237K-$6.4M

Gross margin by year

2021 → 2025

FY 202121.9%FY 202213.6%FY 20239.8%FY 202411.5%FY 20253.4%
21.9%3.4%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 6-K filed Apr 30, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 6-K filingWarrant IssuanceJun 22, 2026Filing
  • 6-K filingSecurities Purchase AgreementJun 9, 2026Filing
  • 6-K filingNasdaq Listing ApprovalJun 9, 2026Filing
  • 6-K filingExercise Price AdjustmentJun 3, 2026Filing
  • 6-K filingWarrant IssuanceMay 12, 2026Filing
  • Annual reportAnnual Report FiledApr 30, 2026Filing
  • 6-K filingWhite Label AgreementApr 23, 2026Filing
  • Annual reportAnnual Report FiledApr 6, 2026Filing
  • Annual report20-F FiledApr 1, 2026Filing

Questions

Frequently asked questions

What is Nexera Technologies Ltd's market cap?

Nexera Technologies Ltd (NEXR) has a market capitalization of $1M.

What is NEXR's P/E ratio?

A meaningful P/E ratio is not available for NEXR — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is NEXR's price-to-book (P/B) ratio?

NEXR trades at 0.09 times book value per share.

Are insiders buying NEXR stock?

SEC Form 4 filings show no open-market insider buys at Nexera Technologies Ltd in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

SXTP

60 Degrees Pharmaceuticals, Inc.

$1.2M

VRAX

Virax Biolabs Group Limited

$769K

AIM

AIM ImmunoTech Inc.

$1.3M

ASBP

Aspire Biopharma Holdings, Inc.

$627.6K

SCNI

Scinai Immunotherapeutics Ltd.

$604.8K

BDRX

Biodexa Pharmaceuticals Plc

$573.7K

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.